Myocardial Infarction (MI) remains one of the most critical emergencies in cardiovascular medicine, driven by acute coronary artery occlusion and rapid onset myocardial necrosis. Early diagnosis and timely reperfusion are essential for preserving viable myocardium, reducing complications and improving survival. Despite major advances in reperfusion therapy, mechanical support and imaging technologies, MI continues to impose a substantial clinical and economic burden worldwide, prompting clinicians to seek up-to-date insights through advanced learning platforms and expert-led cardiology conference discussions that highlight evolving diagnostics, risk stratification and post-MI care pathways.

Myocardial infarction presents in diverse clinical forms: STEMI, NSTEMI, silent ischemia and infarction with non-obstructive coronary arteries (MINOCA). Each subtype requires tailored investigation and management. The session explores ECG interpretation, biomarker profiling, coronary angiography and advanced imaging modalities used to assess infarct size, microvascular obstruction, myocardial viability and risk of remodeling. Early identification of reperfusion candidates, use of thrombolytics in resource-limited settings and optimal timing of percutaneous coronary intervention are critical aspects covered in detail.

Because MI is closely associated with acute coronary syndrome, this programme examines the interplay between plaque rupture, coronary thrombosis, inflammation and endothelial dysfunction. Case discussions illustrate how to manage complex presentations with cardiogenic shock, arrhythmias, mechanical complications such as papillary muscle rupture or ventricular septal defects, and post-infarction pericarditis. Attendees will also learn how to recognise atypical or high-risk presentations in elderly patients, women, diabetics and individuals with silent ischemia.

Post-infarction management is equally critical. The session highlights guideline-directed therapy including dual antiplatelet regimens, anticoagulation strategies, high-intensity statins, beta-blockers, ACE inhibitors, ARBs, SGLT2 inhibitors and emerging cardioprotective agents. Structured cardiac rehabilitation programmes, lifestyle modification, psychosocial support and adherence counselling are also emphasised for long-term prognosis.

Risk stratification tools—including GRACE and TIMI scores—support decision-making regarding invasive strategies, while imaging approaches such as MRI viability assessment and echo-based strain analysis help guide long-term treatment planning. Attendees will understand how residual ischemia, ventricular remodeling and infarct fibrosis shape outcomes and determine the need for device therapy or surgical intervention.

Emerging research areas include cardioprotective pharmacology, novel antithrombotic strategies, hybrid revascularisation approaches, regenerative techniques and AI-assisted interpretation of imaging and ECG data. This comprehensive session equips clinicians with the expertise needed to diagnose MI rapidly, initiate appropriate treatment and support long-term recovery.